Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Jun 202012

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.    

Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 06-18-12). As a matter of disclosure : The author continues to be a current shareholder in the company.

The Senesco Technologies web site ( https://www.senesco.com/cancer.htm; obtained on 6-18-12) has posted relevant information about its research on cancer. Here is an excerpt:

“There are two major apoptosis pathways triggered by the immune system: the DNA damage pathway and the death receptor pathway. We have demonstrated that modulation of eIF5A can induce apoptosis through both of these pathways in multiple human cancer cell lines.

Consequently we believe that our approach to cancer treatment should be applicable to most, if not all, types of cancer.

Our findings indicate that eIF5A expression activates the DNA damage pathway by up-regulating the expression of p53, which promotes apoptosis.

Human multiple myeloma cell lines (KAS-6/1 and RPMI 8226) were used to establish subcutaneous tumors in severe combined immunodeficiency (SCID) mice. When eIF5A siRNA or eIF5AK50R were administered separately reductions of multiple myeloma tumor growth of 80% and 70%, respectively, were observed compared to controls. When both components were delivered in combination, significantly greater tumor growth inhibition of 94% was measured.

The application of eIF5A in the treatment of solid and disseminated tumors has been investigated in mouse models of melanoma and lung cancer. Intravenous administration of eIF5A plasmid significantly inhibited growth of disseminated melanoma tumors in the lung, resulting in a 59% decrease in lung weight (a measure of tumor burden) compared to control animals. [Jin S, Taylor CA, Liu Z, Sun Z, Ye B, Thompson JE. Suppression of Primary and Disseminated Murine Tumor Growth with eIF5A1 Gene Therapy. Gene Ther Mol Biol Vol 12, 207-218, 2008].”


The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.                                    © 2012 The Hygiology Post